BRIEF published on 09/11/2026 at 12:06, 1 day 1 hour ago ABL Diagnostics dépose une offre publique d'achat sur IntegraGen. Offre Publique D'achat Diagnostic Moléculaire IntegraGen Diagnostics ABL Analyse Génomique
BRIEF published on 09/11/2026 at 12:06, 1 day 1 hour ago ABL Diagnostics Files Takeover Bid for IntegraGen Molecular Diagnostics Takeover Bid IntegraGen ABL Diagnostics Genomic Analysis
PRESS RELEASE published on 09/11/2026 at 12:01, 1 day 1 hour ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) ABL Diagnostics annonce le dépôt d'une offre de reprise d'IntegraGen, société spécialisée en analyse génomique, dans le cadre de sa stratégie de croissance externe Croissance Externe Offre De Reprise IntegraGen ABL Diagnostics Analyse Génomique
PRESS RELEASE published on 09/11/2026 at 12:01, 1 day 1 hour ago Inside Information / Operations of the issuer (acquisitions, sales...) ABL Diagnostics announces takeover bid for IntegraGen, a genomic analysis company. Acquisition subject to Commercial Court decision. ABLD focuses on molecular diagnostics solutions and growth strategy Growth Strategy Molecular Diagnostics Takeover Bid IntegraGen ABL Diagnostics
BRIEF published on 07/23/2026 at 16:01, 1 month 19 days ago Franchissement à la baisse du seuil de 95 % pour ABL Diagnostics Stratégie De Croissance Liquidité Du Titre Actionnaire Majoritaire ABL Diagnostics Élargissement Du Flottant
BRIEF published on 07/23/2026 at 16:01, 1 month 19 days ago ABL Diagnostics falls below the 95% threshold Growth Strategy Stock Liquidity Majority Shareholder ABL Diagnostics Widening Of The Floating
PRESS RELEASE published on 07/23/2026 at 15:56, 1 month 19 days ago Informations privilégiées Autres communiqués ABL Diagnostics informe du franchissement du seuil de 95% par son actionnaire de référence, ABL, dans le cadre de sa stratégie d'élargissement du flottant conformément à ses engagements Stratégie ABL Diagnostics Actionnaire De Référence Franchissement Seuil Élargissement Flottant
BRIEF published on 07/23/2026 at 09:27, 1 month 20 days ago ABL Diagnostics reprend les activités de TEXCELL Investissement ABL Diagnostics Virologie TEXCELL Reprise Genopole
BRIEF published on 07/23/2026 at 09:27, 1 month 20 days ago ABL Diagnostics takes over TEXCELL's activities Investment ABL Diagnostics Virology Genopole TEXCELL Takeover
PRESS RELEASE published on 07/23/2026 at 09:22, 1 month 20 days ago Informations privilégiées / Autres communiqués ABL Diagnostics désignée pour la reprise des activités de TEXCELL, renforçant ainsi les synergies en virologie, biosécurité et contrôle biologique, avec un programme d'investissements et une continuité stratégique Investissements Reprise Synergies ABL Diagnostics Virologie
Published on 09/12/2026 at 02:35, 10 hours 54 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 29 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 24 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 4 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 29 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 5 hours 59 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 14 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 19 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 44 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 14 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 17 hours ago Availability of the 2026 Interim Financial Report
